Sharemaestro Newsreel

Eikon Therapeutics, Inc. Stock 12‑Month Price Target Cut to $24.6, Implies 138% Upside

Eikon Therapeutics, Inc.'s average 12-month price target has been lowered to $24.6 from $24.8 by 5 analysts, with individual forecasts ranging from $4 to $32 per share. This new target suggests a potential upside of approximately 138% based on the August 13 closing price. …

Armistice Capital (BCYC) reports 3.40M Bicycle Therapeutics ADSs in 13G/A

Armistice Capital, LLC and Steven Boyd have filed an amended Schedule 13G, reporting beneficial ownership of 3,398,000 American Depositary Shares (ADSs) of Bicycle Therapeutics plc (BCYC). This represents 6.72% of the outstanding class as of June 30, 2026. All voting and dispositive power over …

Teleflex (TFX) Stock Looks Undervalued On Cash Flow But Overvalued On Sales

Teleflex (TFX) stock appears undervalued based on a Discounted Cash Flow (DCF) model, suggesting a 46.8% discount from its intrinsic value due to strong free cash flow and planned debt reduction and buybacks. However, the stock screens as overvalued on a Price/Sales (P/S) multiple …

Trinity Biotech (TRIB) adds $7M Perceptive funding and cures Nasdaq bid-price issue

DFTX News Today | Why did Definium Therapeutics stock go down today?

Labcorp announces executive leadership changes effective in September

Labcorp (NYSE:LH) has announced executive leadership changes effective in September. Megan D. Bailey is resigning as Executive Vice President and President, Central Laboratories and International, effective September 4, 2026. Brian J. Caveney, M.D., will assume an expanded role as Executive Vice President and President, …

Earnings call transcript: Lantern Pharma posts q2 2026 loss miss as stock slips

Is Lifeward Ltd (LFWD) Positioned for Growth After Q2 Earnings?

Earnings call transcript: ImmuCell posts strong Q2 2026 sales growth, shares fall

AstraZeneca stock trades around $157 as Q2 2026 EPS beats expectations

MDxHealth SA Stock 12‑Month Price Target Cut to $2.2, Implies 376% Upside

MDxHealth SA's average stock price target has been reduced from $2.8 to $2.2 by analysts, with individual forecasts ranging from $1 to $4. This updated target suggests a potential upside of approximately 376% from its recent closing price. The consensus rating for the stock …

Spectral AI (MDAI): LMR funds report 6.2% beneficial stake via warrants

LMR-affiliated investment entities have reported a 6.2% beneficial ownership stake in Spectral AI, Inc. (MDAI) as of June 30, 2026. This ownership is primarily through warrants exercisable for 2,106,358 shares of Common Stock, with LMR Master Fund and LMR CCSA Master Fund each holding …

Earnings call transcript: PAVmed narrows Q2 2026 loss as shares slip

PAVmed Inc. (PAVM) reported a narrower GAAP net loss of $5.5 million, or $0.87 per share, in Q2 2026, down from $12.3 million a year earlier, driven by lower non-cash charges. Despite progress in its Lucid Diagnostics, Veris, PortIO, and Octeris programs, the stock …

Hims & Hers Health raises 2023 revenue outlook after strong Q2 growth despite margin drop

Werewolf Therapeutics Company Profile & Introduction

Bausch Health Stock Gains Momentum as Stronger Earnings, Raised Outlook and Debt Progress Lift Investor Optimism

Fresenius Medical Care stock steadies around $23 as investors weigh recent buybacks and guidance

Fresenius Medical Care stock is trading steadily around $23 in mid-August 2026, influenced by recent share buybacks and a modest year-to-date decline. The company's capital allocation strategy now includes renewed willingness for buybacks, alongside guidance for continued mid-single-digit revenue growth and improved operating income …

Armistice Capital (CALC) discloses 3.41M-share, 9.99% holding in CalciMedica

Armistice Capital, LLC and Steven Boyd have reported a significant holding in CalciMedica, Inc., disclosing beneficial ownership of 3,411,361 shares, which represents 9.99% of the company's common stock. The shares are directly held by Armistice Capital Master Fund Ltd., with Armistice Capital serving as …

Forte Biosciences earnings on deck as $2.2 billion argenx deal nears

Forte Biosciences is set to report its second-quarter earnings, which are expected to be largely a formality as the company awaits the completion of its $2.2 billion acquisition by argenx. Analysts anticipate a loss of $1.01 per share on zero revenue for Forte. The …

ARDX SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Ardelyx

SueWallSt has initiated an investigation into potential securities law violations by Ardelyx (NASDAQ: ARDX) following a significant drop in its stock price. The company lowered its 2026 IBSRELA revenue guidance by up to $80 million and withdrew its long-term XPHOZAH revenue target, citing payer …

Armistice Capital (BTAI) discloses 4.99% BioXcel Therapeutics stake via managed fund

Armistice Capital, LLC and Steven Boyd have reported a beneficial ownership of 4.99% in BioXcel Therapeutics, Inc. (BTAI), amounting to 1,621,716 shares. These shares are held through Armistice Capital Master Fund Ltd., with Armistice Capital exercising shared voting and dispositive power as the investment …

Vertex Pharmaceuticals: I Was Wrong About Its Near-Term Prospects (Rating Upgrade)

Are Investors Undervaluing Tenet Healthcare (THC) Right Now?

Here at Zacks, we focus on our proven ranking system, which places an emphasis on earnings estimates and estimate revisions, to find winning stocks. But we also understand that investors develop their own strategies, so we are constantly looking at the latest trends in …

Trinity Biotech secures $7m from Perceptive Advisors By Investing.com

Trinity Biotech (NASDAQ:TRIB) has secured an additional $7.0 million investment from Perceptive Advisors, its largest financial investor, comprising $2.5 million in new debt and $4.5 million in capitalized interest. This funding will support the company's CGM+ continuous glucose monitoring platform, Trinovium subsidiary, and diagnostics …

Form 8K Lifeward Ltd. For: 14 August By Investing.com

This article reports on the filing of Form 8K by Lifeward Ltd. on August 14th. It appears to be a standard financial news brief from Investing.com, providing basic information about the filing and its publication details.

Quantum Biopharma Ltd. (CN:QNTM) Shares Decline as Biotech Uncertainty, Funding Risks and Clinical Development Challenges Pressure Investor Sentiment

Is Phase III Rezpegaldesleukin And Cash Runway Progress Altering The Investment Case For Nektar Therapeutics (NKTR)?

Why Did Oscar Health (OSCR) Fall After Record Profit and a Guidance Hike?

Oscar Health, Inc. (NYSE:OSCR) shares closed 11.9% lower at $26.54 on August 6, even after the insurer reported its most profitable first half and raised its full-year outlook. Second-quarter revenue rose 70% year over year to $4.88 billion, while the company swung to net …

Trinity Biotech Secures Additional $7.0 Million Investment from Perceptive Advisors and Regains Compliance with Nasdaq Minimum Bid Price Requirement

Trinity Biotech (NASDAQ: TRIB) has secured an additional $7.0 million investment from Perceptive Advisors, its largest financial investor, and has regained compliance with Nasdaq's minimum bid price requirement. The investment, consisting of new debt funding and capitalized interest, aims to bolster liquidity for strategic …

Trinity Biotech Regains Nasdaq Compliance After 10 Days at $1 or More

Canton Strategic Holdings (CNTN) posts $66.6M loss amid big Canton Coin bet

Embecta (EMBC) Q3 2026 Earnings Call Transcript

Rapid Micro Biosystems (RPID) Q2 2026 Earnings Call Transcript

DOCS|Doximity Inc|Price:26.375|Chg%:-0.215

JonesTrading Forecasts Strong Price Appreciation for Trevi Therapeutics (NASDAQ:TRVI) Stock

Tenet Healthcare Corporation (THC) Hits Fresh High: Is There Still Room to Run?

Shares of Tenet Healthcare (THC) have been strong performers lately, with the stock up 34.1% over the past month. The stock hit a new 52-week high of $270.57 in the previous session. Tenet has gained 34.4% since the start of the year compared to …